Physician profile
James S Walker
NPI 1932218971
$5,231.74
in general payments reported to CMS, 2019-2025
34 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $385 · 2021: $309 · 2022: $859 · 2023: $1,269 · 2024: $1,102 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,109.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,006.47 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $642.25 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $433.65 | 2019-2024 | |
| Lilly USA, LLC | $373.67 | 2019-2025 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $227.47 | 2019-2025 | Belsomra, Capvaxive, Verquvo |
| Kowa Pharmaceuticals America, INC. | $208.95 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $201.34 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $112.73 | 2022-2025 | |
| Amarin Pharma, INC. | $105.23 | 2020-2022 | |
| Sanofi Pasteur INC. | $79.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $70.67 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.38 | 2021-2023 | Synjardy, Glyxambi, Trijardy Xr |
| Abbvie INC. | $65.28 | 2023-2024 | Qulipta, Ubrelvy |
| Shield Therapeutics INC | $44.21 | 2023-2024 | Accrufer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $43.40 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $35.79 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $33.52 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $32.11 | 2019-2022 | |
| Ibsa Pharma INC. | $28.62 | 2022 | |
| Radius Health, INC. | $27.94 | 2019-2020 | |
| Phadia US INC. | $22.22 | 2024 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $21.54 | 2023 | Trintellix |
| Dexcom, INC. | $20.54 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $19.37 | 2025 | Gemtesa |
| Corcept Therapeutics | $19.00 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $17.26 | 2023 | Nexletol |
| Currax Pharmaceuticals LLC | $17.01 | 2023 | Contrave |
| Teva Pharmaceuticals USA, INC. | $16.83 | 2019 | |
| Tolmar, INC. | $16.77 | 2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.34 | 2023 | Trulance, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $14.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.26 | 2019 | |
| Vistapharm, INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.